Results 351 to 360 of about 1,844,871 (401)
Some of the next articles are maybe not open access.
2021
Chronic heart failure (CHF) is currently an important health problem causing significant mortality and morbidity. There are highly effective medical treatments used in the treatment of chronic heart failure, and standard treatment guidelines provide the most efficient treatment benefits.
openaire +2 more sources
Chronic heart failure (CHF) is currently an important health problem causing significant mortality and morbidity. There are highly effective medical treatments used in the treatment of chronic heart failure, and standard treatment guidelines provide the most efficient treatment benefits.
openaire +2 more sources
2009
Heart failure is the leading cause of hospitalization in the Medicare age group. The prognosis for established heart failure in persons over age 65 is poor, with 5-year survival rates of less than 50% in both men and women. The pharmacotherapy of systolic heart failure is well established, with angiotensin-converting enzyme inhibitors and beta ...
Michael W. Rich, Christopher L. Holley
openaire +2 more sources
Heart failure is the leading cause of hospitalization in the Medicare age group. The prognosis for established heart failure in persons over age 65 is poor, with 5-year survival rates of less than 50% in both men and women. The pharmacotherapy of systolic heart failure is well established, with angiotensin-converting enzyme inhibitors and beta ...
Michael W. Rich, Christopher L. Holley
openaire +2 more sources
Homocysteine in Chronic Heart Failure
Clinical Laboratory, 2015Hyperhomocysteinemia (HHcy) is a risk factor for cardiovascular disease. Homocysteine (Hcy) can generate reactive oxygen species. Oxidative stress enhances the progression of cardiovascular diseases and has long been implicated in chronic heart failure (CHF).
Joelle Fourcade +5 more
openaire +2 more sources
Economics of chronic heart failure
European Journal of Heart Failure, 2001AbstractChronic heart failure (CHF) is now recognized as a major and escalating public health problem. The costs of this syndrome, both in economic and personal terms, are considerable. The prevalence of CHF is 1–2% and appears to be increasing, in part because of ageing of the population.
David R. Murdoch +2 more
openaire +2 more sources
[ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?]
Giornale italiano di cardiologia, 2022G. Sinagra, L. Pagura, D. Stolfo
semanticscholar +1 more source
Testosterone in Chronic Heart Failure
2008Chronic heart failure is common and can be described as a syndrome characterized by impairment of cardiac function associated with a maladaptive metabolic and neurohormonal axis. The thesis that testosterone replacement therapy may be helpful as a treatment for chronic heart failure may seem at first to be unlikely.
KS Channer, Chris J. Malkin, T. H. Jones
openaire +3 more sources
Erythropoietin in Chronic Heart Failure
Congestive Heart Failure, 2007In patients with chronic heart failure (CHF), anemia is common and is associated with adverse outcome. Correction of anemia by erythropoiesis‐stimulating proteins would thus seem attractive. Endogenous erythropoietin (Epo) levels are increased in CHF and are associated with severity of the disease and with increased mortality.
Anne M. S. Belonje +3 more
openaire +2 more sources
Malnutrition and chronic heart failure
Mediterranean Journal of Nutrition and Metabolism, 2008Malnutrition in patients with chronic heart failure (CHF) is not always as severe as muscle wasting in the same patients. Our data showed that 24% of patients with CHF had malnutrition (serum albumin < 3.5 g/dl) while 68% had muscle atrophy. This apparent discrepancy can be explained by considering the metabolic role of the striate muscle.
E. Pasini, R. Aquilani, F.S. Dioguardi
openaire +2 more sources
Bisoprolol in chronic heart failure
Hospital Medicine, 2000The evidence for the use of beta-blockers in heart failure is substantial. Latest recommendations and guidelines suggest that most heart failure patients should be on a drug regimen of an angiotensin-converting enzyme inhibitor, diuretic and a beta-blocker.
openaire +2 more sources